HCM · NASDAQ

HUTCHMED (China) Limited

Q: How do I get HCM news from the API?

Call GET /v1/news?tickers=HCM. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.

$14.28 +0.08 (+0.56%)

Company overview

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. It operates through Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: NASDAQ
Market cap: $2.5B
Employees: 1,811
Headquarters: Hong Kong
Website: hutch-med.com
CEO: Chig Fung Cheng
Listed: March 16, 2016
P/E: 5.16
Dividend yield: 0.00%

Company financials

Revenue: $602M
Gross profit: $53.8M
Operating income: -$19.7M
EBITDA: -$7.5M
Net income: $467M
EPS: $2.77
Total assets: $1.8B
Total debt: $97.9M
Gross margin: 8.93%
Net margin: 77.53%
Earnings yield: 19.40%

Revenue segmentation

By product (FY 2025)

By region (FY 2025)

Showing FY 2025

Price chart

HCM 1D NASDAQ O14.28H14.30L14.28C14.29-0.07 (-0.52%)Vol1.07K

News

Ticker	Type	Headline	Source	Published
HCMHUTCHMED (China) Limited	Press release	Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer	GlobeNewswire	Oct 26, 8:00:00 PM ET
HCMHUTCHMED (China) Limited	Press release	HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026	GlobeNewswire	Oct 26, 4:30:00 AM ET
HCMHUTCHMED (China) Limited	Press release	HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine	GlobeNewswire	Oct 25, 8:00:00 PM ET
HCMHUTCHMED (China) Limited	Press release	Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy	GlobeNewswire	Oct 23, 8:30:00 AM ET
HCMHUTCHMED (China) Limited	Press release	HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China	GlobeNewswire	Oct 20, 8:00:00 PM ET
HCMHUTCHMED (China) Limited	Stock news	HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Has Consensus Price Target of $14.87 According to Analysts	Defense World	Oct 16, 2:59:04 AM ET
HCMHUTCHMED (China) Limited	Stock news	Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More	Seeking Alpha	Sep 30, 2:38:20 PM ET
HCMHUTCHMED (China) Limited	Press release	HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer	GlobeNewsWire	Sep 28, 8:00:00 PM ET
HCMHUTCHMED (China) Limited	Press release	HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors	GlobeNewsWire	Sep 27, 8:00:00 PM ET
HCMHUTCHMED (China) Limited	Press release	HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026	GlobeNewsWire	Sep 23, 8:00:00 PM ET
HCMHUTCHMED (China) Limited	Stock news	Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data	MarketBeat	Sep 20, 1:02:05 PM ET
HCMHUTCHMED (China) Limited	Stock news	HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy	MarketBeat	Sep 3, 1:03:17 PM ET
HCMHUTCHMED (China) Limited	Stock news	HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript	Seeking Alpha	Sep 3, 10:39:17 AM ET
HCMHUTCHMED (China) Limited	Stock news	Panmure and Cavendish reiterate buy on Hutchmed after GSK deal	Proactive Investors	Sep 3, 6:33:57 AM ET
SNOW	Stock news	Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket	Benzinga	Sep 3, 4:43:49 AM ET
HCMHUTCHMED (China) Limited	Stock news	HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal	Proactive Investors	Sep 3, 3:51:38 AM ET
HCMHUTCHMED (China) Limited	Stock news	HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug	Reuters	Sep 3, 1:48:04 AM ET
HCMHUTCHMED (China) Limited	Press release	HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy	GlobeNewsWire	Sep 3, 12:00:00 AM ET
HCMHUTCHMED (China) Limited	Press release	HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China	GlobeNewsWire	Aug 30, 8:00:00 PM ET
HCMHUTCHMED (China) Limited	Press release	HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma	GlobeNewsWire	Aug 27, 8:00:00 PM ET

FAQ

Questions about HUTCHMED (China) Limited

What does HUTCHMED (China) Limited do?

What is HCM's market cap?

HUTCHMED (China) Limited (HCM) is a listed stock with a live quote. The latest market cap on this page is $2.5B.

Where is HUTCHMED (China) Limited headquartered?

HUTCHMED (China) Limited is headquartered in Hong Kong.

How do I get HCM news from the API?

Call GET /v1/news?tickers=HCM. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.

How far back does HCM news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for HCM, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.

Is the HCM price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs